Trial Profile
A Single-arm Study of the Safety, Efficacy and Central Nervous System and Plasma PK of GSK1349572 (Dolutegravir, DTG) 50 mg Once Daily in Combination With the Abacavir/Lamivudine Fixed Dose Combination Tablet Over 96 Weeks in HIV-1 Infected Antiretroviral Naive Adult Subjects.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 07 Sep 2023
Price :
$35
*
At a glance
- Drugs Dolutegravir (Primary) ; Lamivudine/abacavir
- Indications HIV infections
- Focus Pharmacokinetics; Registrational
- Sponsors ViiV Healthcare
- 24 Feb 2015 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
- 27 Jun 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 09 Feb 2012 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.